Zura Bio Q2 net loss widens as R&D expenses rise
ZURA•Outlook
- Topline data from TibuSHIELD Phase 2 study expected in Q4 2026
- Topline data from TibuSURE Phase 2 study expected in H1 2027
- Company expects to initiate Phase 2 study in PMR by year-end 2026
- Company expects cash to fund operations through at least end of 2028
Overview
- US biotech firm's Q2 net loss widened yr/yr as R&D expenses rose
- Company completed enrollment in two Phase 2 tibulizumab studies, both exceeding initial targets
- Cash and cash equivalents of $205.1 mln expected to fund operations through at least end of 2028
Key details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Net Loss | $26.30 mln | ||
| Q2 loss from Operations | -$29.32 mln | ||
| Q2 Operating Expenses | $29.32 mln | ||
| Q2 Pretax Loss | $26.39 mln |
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell". The average consensus recommendation for the biotechnology & medical research peer group is "buy." Wall Street's median 12-month price target for Zura Bio Ltd is $15.50, about 175.3% above its August 10 closing price of $5.63.
